Table 2.
Ongoing Clinical Trials of MET Inhibitors in NSCLC
| Category | Agents | Trial ID | Research Time | Sample size | Trial Descriptions | Phase | Primary End Point | |
|---|---|---|---|---|---|---|---|---|
| MET TKI | Ib | Capmatinib | NCT04677595 | 2021–2025 | 35 | METex14 advanced NSCLC | II | ORR |
| Savolitinib | NCT04923945 | 2021–2024 | 163 | METex14 locally advanced or metastatic NSCLC | III | ORR | ||
| Savolitinib + osimertinib | NCT05015608 | 2021–2024 | 250 | MET amplified advanced NSCLC | III | PFS | ||
| NCT05261399 | 2022–2026 | 324 | EGFR-mutated locally advanced or metastatic NSCLC with MET overexpression and/or amplification after Osimertinib resistance | III | PFS | |||
| Gumarontinib | NCT04270591 | 2019–2023 | 183 | c-MET+ advanced NSCLC | Ib/II | ORR | ||
| Bozitinib | NCT04258033 | 2020–2024 | 185 | c-MET+ locally advanced/metastatic NSCLC | II | ORR | ||
| Bozitinib | NCT03175224 | 2017–2026 | 497 | MET-altered (MET fusion, METex14, and MET amplification) NSCLC | I/II | The MTD and the incidence of DLTs; ORR | ||
| Ia | Ensartinib | ChiCTR2100048767 | 2021–2024 | 42 | METex14 advanced or metastatic NSCLC | II | ORR | |
| II | Cabozantinib | NCT01639508 | 2012–2026 | 86 | MET overexpression, amplification, or mutation in NSCLC | II | ORR | |
| Antibody | Amivantamab | NCT02609776 | 2016–2024 | 751 | Previously treated METex14 unresectable or metastatic NSCLC | I | Number of participants with DLTs, AEs and SAEs | |
| Amivantamab+ | NCT05488314 | 2022–2025 | 161 | METex14 or MET amplified metastatic NSCLC | I/II | Number of participants with Aes, DLTs and ORR | ||
| Capmatinib | ||||||||
| ADC | Telisotuzumab Vedotin | NCT03539536 | 2018–2025 | 270 | Previously treated c-Met+ locally advanced or metastatic NSCLC | II | ORR; Number of participants with Aes | |
| NCT05513703 | 2022–2027 | 70 | Previously untreated MET amplified advanced/metastatic nonsquamous NSCLC | II | ORR | |||
| RC108 | NCT04617314 | 2021–2025 | 32 | c-Met + advanced malignant solid tumors | I | Number of participants with AEs; | ||
| Maximum tolerated dose | ||||||||
ADC, antibody-drug conjugate; AE, adverse event; DLT, dose limited toxicity; ICI, immune checkpoint inhibitor; ID, identification; METex14, MET exon 14; MTD, maximum tolerated dose; ORR, objective response rate; PFS, progression-free survival; RR, response rate; SAE, serious adverse event; TKI, tyrosine kinase inhibitor.